# NAD+: Research Overview — Youth Lab Peptides > A literature summary of NAD+ (nicotinamide adenine dinucleotide), the redox coenzyme whose age-related decline anchors modern longevity research. Covers mechanism, human trial data on NMN and NR precursors, and safety cautions. The redox molecule every cell depends on to make energy and repair DNA — and the reason boosting NAD+ has become shorthand for modern longevity research. ## The short version NAD+ (nicotinamide adenine dinucleotide) is not a peptide — it is a small molecule every living cell already makes and depends on. It works two ways: as a **redox carrier**, shuttling electrons through the reactions that turn food into usable energy, and as a **substrate**, meaning enzymes like sirtuins and PARPs consume it to run DNA repair and gene-regulation processes. The reason NAD+ leads this desk is that its levels measurably decline with age, and restoring them — usually via precursor molecules like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) rather than NAD+ itself — has become one of the most active threads in aging research. Human trials have consistently shown these precursors do raise blood NAD+. Whether that translates into a measurable, clinically meaningful anti-aging benefit is a separate and still-open question, one a 2025 review answered cautiously [6]. This page covers what has actually been measured in humans, not what supplement marketing claims — and it does not recommend a dose. ## What it is NAD+ is a dinucleotide — two nucleotides joined by bridging phosphate groups — built from nicotinamide mononucleotide and adenosine monophosphate. It exists in an oxidized form (NAD+) and a reduced form (NADH), and the ratio between the two is itself a marker of cellular metabolic state. Molecular formula C21H27N7O14P2. Because NAD+ itself is broken down before it can cross into cells intact, oral NAD+ supplements are widely considered a poor delivery strategy; the two precursors studied in human trials, NMN and NR, are absorbed and converted to NAD+ inside cells, and IV or injectable NAD+ delivers it directly into the bloodstream rather than through digestion. ## How it works NAD+ sits at the center of cellular energy metabolism, shuttling electrons through glycolysis, the TCA cycle, and oxidative phosphorylation to generate ATP. Separately, it is consumed as a substrate by three families of signaling enzymes: **sirtuins** (SIRT1 through SIRT7), which regulate gene expression and metabolism; **PARPs** (chiefly PARP1), which repair damaged DNA; and **CD38/CD157**, cell-surface enzymes that break NAD+ down and whose activity rises with age and inflammation [9][11]. Because sirtuins, PARPs, and CD38 all draw from the same NAD+ pool, a rising CD38 burden with age is thought to out-compete the other two for a shrinking supply — the mechanistic rationale for why restoring NAD+ levels is studied as an anti-aging strategy. In mice, deleting CD38 preserves NAD+ levels and mitochondrial function into old age, supporting this model [11]. ## What the research shows *Human clinical evidence, synthesized.* A 2025 narrative review of the human trial evidence on NAD+ precursor supplementation in aging concluded that human trials have shown limited efficacy, that age-related NAD+ decline has been consistently observed only in a limited number of human studies, and that tissue-specific NAD+ dynamics remain understudied — calling for more human trials rather than continued extrapolation from rodent data [6]. *NMN, walking distance.* In a multicenter, double-blind randomized trial, oral NMN (300-900 mg/day for 60 days) dose-dependently raised blood NAD+ in middle-aged adults and improved walking distance and quality-of-life scores versus placebo, with 600 mg/day identified as the apparent optimal dose and no safety issues at any dose tested [7]. *NMN, insulin sensitivity.* In prediabetic, postmenopausal women, 10 weeks of oral NMN (250 mg/day) significantly improved muscle insulin sensitivity, measured by hyperinsulinemic-euglycemic clamp, though body composition and HbA1c did not change [8]. *NR, dose-response.* In healthy overweight adults, NR at 100-1000 mg/day for 8 weeks dose-dependently raised whole-blood NAD+ by 22%, 51%, and 142% respectively, with no flushing and no significant difference in adverse events from placebo at any dose [10]. *Mechanism: CD38.* CD38 is the principal NAD+-consuming enzyme whose activity rises with age; CD38-knockout mice are protected from age-related NAD+ decline and retain better mitochondrial function [11]. *Heart failure model.* In human myocardium and a mouse model of heart failure with preserved ejection fraction, restoring oxidized NAD+ reactivated a ketogenic enzyme (HMGCS2), increased fatty-acid oxidation, and rescued cardiac function — a mechanistic link between NAD+ metabolism and cardiac aging [12]. ## Reported effects, cautions & safety Because NAD+ is a coenzyme rather than a peptide most people inject and feel directly, structured personal-experience reports are thinner here than for the other three compounds on this desk. What follows instead is drawn from the published trial-safety data and the documented controversies around NAD+ supplementation and IV therapy — no anecdotal reports are asserted here because none rise to a level worth repeating. The clinical-trial safety record for oral NMN and NR is reassuring within its scope: neither the 60-day NMN trial nor the 8-week NR dose-escalation trial found significant excess adverse events versus placebo at any dose tested, and NR did not raise LDL cholesterol or disrupt one-carbon metabolism [7][10]. That said, the same 2025 review that synthesizes the human trial evidence is explicit that efficacy data remain limited and that tissue-specific NAD+ dynamics are still sparsely characterized — raising blood NAD+ is well demonstrated, but translating that into a hard clinical outcome is not yet established [6]. Two cautions apply specifically to **IV or injectable NAD+**, which is a different delivery route from the oral trials above and rests on far less controlled human evidence: infusions run too quickly are reported to cause chest or abdominal discomfort, flushing, and nausea, and the FDA has issued a Class I recall of a compounded NAD+ injection over elevated bacterial endotoxin — a product-quality risk tied to compounding, not to NAD+ itself. A further theoretical caution, raised in the oncology literature, is that boosting NAD+ could in principle support the metabolism of an existing cancer, since NAD+ also fuels proliferating cells; this is mechanism-based reasoning, not a demonstrated human harm. ## Where it fits in healthspan and cellular-aging research NAD+ is the mechanistic hub this desk organizes around: it is the coenzyme that [BPC-157](/bpc-157)'s repair signaling, [semaglutide](/semaglutide)'s metabolic protection, and [Thymosin Alpha-1](/thymosin-alpha-1)'s immune restoration all ultimately draw energy and DNA-repair capacity from, even though none of the four have been studied together directly. Of the four, NAD+ has the most human dosing trials but arguably the least settled translation from biomarker change (raised blood NAD+) to a clinical outcome anyone would call anti-aging. See the [comparison page](/compare) for how its evidence maturity stacks up against the other three. ![NAD+ research illustration — abstract cellular redox pathway motifs](/images/nad.webp) --- Youth Lab Peptides is an independent, citation-anchored reading room on healthspan and cellular-aging research — not a clinic, not a supplier, and not a source of medical advice.